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Abstract
Recent genome-wide association studies (GWASs) have identified candidate genes contributing to cancer risk through low-
penetrance mutations. Many of these genes were unexpected and, intriguingly, included well-known players in
carcinogenesis at the somatic level. To assess the hypothesis of a germline-somatic link in carcinogenesis, we evaluated the
distribution of somatic gene labels within the ordered results of a breast cancer risk GWAS. This analysis suggested frequent
influence on risk of genetic variation in loci encoding for ‘‘driver kinases’’ (i.e., kinases encoded by genes that showed higher
somatic mutation rates than expected by chance and, therefore, whose deregulation may contribute to cancer
development and/or progression). Assessment of these predictions using a population-based case-control study in Poland
replicated the association for rs3732568 in EPHB1 (odds ratio (OR)=0.79; 95% confidence interval (CI): 0.63–0.98;
Ptrend=0.031). Analyses by early age at diagnosis and by estrogen receptor a (ERa) tumor status indicated potential
associations for rs6852678 in CDKL2 (OR=0.32, 95% CI: 0.10–1.00; Precessive=0.044) and rs10878640 in DYRK2 (OR=2.39, 95%
CI: 1.32–4.30; Pdominant=0.003), and for rs12765929, rs9836340, rs4707795 in BMPR1A, EPHA3 and EPHA7, respectively (ERa
tumor status Pinteraction,0.05). The identification of three novel candidates as EPH receptor genes might indicate a link
between perturbed compartmentalization of early neoplastic lesions and breast cancer risk and progression. Together,
these data may lay the foundations for replication in additional populations and could potentially increase our knowledge
of the underlying molecular mechanisms of breast carcinogenesis.
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Introduction
With the advent of technical and methodological advances,
several GWASs identifying common genetic variation associated
with risk of developing cancer have been completed recently [1].
Thus, initiatives such as the National Cancer Institute’s Cancer
Genetic Markers of Susceptibility (CGEMS) and efforts carried out
by deCODE Genetics and the Breast Cancer Association
Consortium have led to the identification of breast cancer risk
alleles in single nucleotide polymorphisms (SNPs) replicated across
populations [2–6]. Intriguingly, illustrating the unbiased nature of
GWASs, most hits have corresponded to a priori unexpected
candidate genes. In this context, the involvement of biological
processes beyond the canonical DNA damage response in breast
cancer is further suggested by the observed differential influence of
low-penetrance risk alleles among BRCA1 and BRCA2 mutation
carriers [7–9].
A potential common characteristic of the unexpected low-
penetrance susceptibility genes is the previously identified
contribution to tumorigenesis, but at the somatic level. Common
genetic variation in loci encoding for FGFR2 and MAP3K1
influences risk of breast cancer [2,4], and these genes were
previously found to be somatically mutated in diverse neoplasias
including breast cancer [10,11]. In addition, and central to the
understanding of cancer progression, common risk alleles showed
differential influence according to ERa tumor status [12], and
variation in the locus encoding for ERa, ESR1, also influences risk
of breast cancer [13,14]. More recently, additional breast cancer
susceptibility loci have been described that include CDKN2A/B as
candidates [15]. While these observations suggest a ‘‘germline-
somatic’’ link in breast carcinogenesis, an analogous situation may
exist for other neoplasias. Variation in loci encoding for CDH1 and
SMAD7 influences risk of colorectal cancer [16,17] and, similarly,
these genes were previously identified as inactivated or deregulated
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a paradigmatic proto-oncogene, MYC, may be a common
mechanism of tumorigenesis in epithelial tissues [22–25]. Howev-
er, despite some evidence of a germline-somatic link, as yet there is
no explicit evaluation of this hypothesis and its potential usefulness
in replication studies. Here we present an examination of this link
through analysis of the CGEMS GWAS breast cancer dataset and
subsequent assessment of the predictions in a case-control study of
incident breast cancer in Poland.
Results
Distribution of somatic gene sets in ordered breast
cancer GWAS results
Previously, analysis of the CGEMS GWAS dataset using the
lowest genotypic P value per gene locus suggested true associations
in genes annotated with Gene Ontology (GO) biological process
terms linked to somatic events [26,27]. However, since there is a
positive correlation between the extension of a given locus and the
number of SNPs it may contain (and, therefore, the possibility of
significant association results being obtained by chance), an
unadjusted GWAS rank is biased at its lowest P values for specific
processes in which large gene products frequently participate
[26,28,29] (Fig. 1A). Nevertheless, cancer genes tend to expand
across large genomic regions [30], and examination of eight genes
likely involved in breast cancer through low-penetrance muta-
tions–CASP8, COX11, ESR1, FGFR2, LSP1, MAP3K1, RAD51L1
and TOX3 [2–6,13,14]–showed a trend for larger genomic loci
(mean (x) genomic extension=211 kilo bases (kb) and standard
deviation (s)=283 kb; compared to x=66 kb and s=128 kb for
all annotated genes in the CGEMS GWAS rank).
Having identified caveats to the ranking of GWAS results, we
performed 10,000 permutations of case-control status and used the
null distribution of t statistics from the age-adjusted partial
correlation analysis to correct the original rank, which then
showed an unbiased distribution (Fig. 1B). Prior to the evaluation
of somatic sets, analysis of GO biological process terms in the
GWAS permutation P values rank did not show any significant
asymmetry using the Gene Set Enrichment Analysis (GSEA) tool
[31] with multiple testing correction by the false discovery rate
(FDR) approach [32]. Nonetheless, most processes with nominally
significant P values were those previously highlighted, which are
associated with somatic events [26,27] (Table S1). This observa-
tion appears to agree with recently described results of pathway-
based analysis of the same GWAS dataset [33].
Next, evaluation of somatic sets related to cancer prognosis and
treatment response prediction, and to genetic and genomic
alterations (see Materials and Methods), revealed significant
asymmetrical distribution of ‘‘driver kinases’’ [34,35]; that is,
kinases whose deregulation through frequent somatic mutation
contributes to tumor development and/or progression (‘‘driver
mutations’’). In contrast, ‘‘passenger mutations’’ were defined as
essentially neutral and linked to the inherent genetic instability in
cancer cells [34,35]. Thus, the driver kinases set was found to be
biased towards the top (nominal significant association results) of
the GWAS permutation rank (GSEA nominal P,0.001; FDR-
adjusted P=0.010) (Fig. 1C and Table S2). Among the remaining
of somatic sets evaluated, only cooperation response genes (CRGs)
to oncogenic mutations [36] showed a trend for a distribution
similar to that of driver kinases (GSEA nominal P=0.080; FDR-
adjusted P value=0.25) (Fig. 1D), although the intersection
between both sets only contained two genes (Table S2). Therefore,
in somatic cancer genes, common genetic variation in driver
kinase loci might frequently influence risk of breast cancer.
The set of driver kinases contained a benchmark gene, FGFR2
[2,4], and a locus recently replicated in an independent study,
BMPR1B [37]. Nevertheless, a significant bias was still observed
following exclusion of these two loci (GSEA nominal P=0.001;
FDR-adjusted P=0.048), which suggests that variation at
additional driver kinase loci influences risk of breast cancer.
Importantly, using the set of non-driver kinases–either the
subsequent equivalent set as originally statistically ordered or the
total set (n=344) [35]–did not reveal significant bias (GSEA
nominal P=0.99 and 0.66, respectively), which reinforces the idea
of frequent involvement of driver kinases. However, if only the
individual statistical data for each locus were considered, most of
the driver kinase loci would perhaps not have been selected for
replication in other populations.
Independent association results for common variation in
driver kinase loci
Given the possible bias in GWAS rank identified above, we
examined the top 20 driver kinase variants in the original rank
(Table S3, including details of the CGEMS and results below) in a
case-control study of incident breast cancer in Szczecin (Poland),
previously used in other replications [38]. Applying genotyping
quality controls and Hardy-Weinberg equilibrium analysis, 16
SNPs representing an identical number of driver kinase loci (i.e., a
single SNP for each locus and representing the strongest potential
statistical association) were examined for their association with risk
of breast cancer using 880 controls and 1,173 cases (see Materials
and Methods). In this analysis, the rs3732568 variant in the ephrin
type-B receptor 1 (EPHB1) locus was found to be associated with risk
of breast cancer: OR=0.79, 95% CI: 0.63–0.98; Ptrend=0.031
(Table 1). Further evaluation of this association through 10,000
case-control permutations in our study gave a similar significance
value, Ptrend=0.034. Importantly, this association was in the same
direction and with similar magnitude to the result in the CGEMS
GWAS: age-adjusted OR=0.78, 95% CI: 0.64–0.94;
Ptrend=0.009.
While deregulated expression or function of EPHs and EPH
receptors is thought to play a critical role in the initial stages of
epithelial neoplasia [39,40], recent analysis of early breast cancer
expression changes suggests a link between disruption of cell
adhesion and extracellular matrix pathways, and the risk of
developing breast cancer [41]. Analysis of this recent dataset also
revealed an early expression change of EPHB1, between normal
breast tissue and atypical ductal hyperplasia (Fig. 2). This
alteration consisted of infra-expression in hyperplasia, akin to its
potential role in the compartmentalization of early neoplastic
lesions [42]. Together, association studies, early expression
changes in carcinogenesis and the regulation of cell adhesion
suggest the involvement of EPHB1 in risk of breast cancer.
Next, given accepted models of inherited breast cancer
susceptibility [43], we examined associations with risk at early
age of diagnosis (#40 years old). This analysis indicated two
additional potential associations: rs6852678 in CDKL2, recessive
model OR=0.32, 95% CI: 0.10–1.00; P=0.044; and rs10878640
in DYRK2, dominant model OR=2.39, 95% CI: 1.32–4.30;
P=0.003 (Table 2). Results for rs6852678 appeared to be
consistent with CGEMS GWAS analysis; age-adjusted recessive
model OR=0.71, 95% CI: 0.53–0.95; P=0.019; however, the
pattern for rs10878640 might be more complex (CGEMS GWAS
ORs=1.05 and 0.68 for heterozygotes and minor allele
homozygotes, respectively).
Having potential differences by ERa tumor status, we next
examined associations in ERa-positive and -negative breast cancer
patients. Thus, rs3732568 in EPHB1 showed a similar influence on
Germline-Somatic Cancer Link
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overall significant association–and rs12765929 in BMPR1A and
rs9836340 in EPHA3 showed a potential major impact on the risk
of ERa-negative breast cancer (P for difference in OR (interaction)
by ERa status ,0.05), while rs4707795 in EPHA7 showed a
differential effect between ERa-negative versus ERa-positive
breast cancer risk (Pinteraction=0.007) (Table 3). None of these
additional candidates linked to ERa tumor status, or those linked
to an early age of diagnosis above, showed significant expression
differences at early stages of breast carcinogenesis as EPHB1.O n
the other hand, the remaining SNPs examined in this study after
applying quality controls and Hardy-Weinberg equilibrium
analysis (i.e., 10 out of 16), did not show significant associations
following CGEMS evidence (Table S3). Together, the gene-set
based analysis of GWAS data and the subsequent replication
attempt might indicate that common genetic variation in specific
driver kinase loci, and particularly in EPH receptor genes, influence
risk of breast cancer.
Discussion
Evaluation of a germline-somatic link in breast carcinogenesis
suggests a role for driver kinases and, perhaps to a lesser extent,
genes with a synergistic response to oncogenic mutations. This
study might be limited by the assignment of the lowest genotypic P
value per gene locus within a defined genomic window (i.e.,
Figure 1. GWAS ranks and distribution of cancer somatic gene sets. A, Original GWAS results ranked according to the lowest genotypic
association test P value per gene locus (unadjusted for genomic extension; taken SNPs in defined genomic window of 610 kb relative to the first and
last exons of a given gene). The Y-axis indicates the number of SNPs per gene locus while the X-axis indicates the lowest association P value per gene
locus. Bias can be appreciated as the number of SNPs per gene locus increases at lower P values. B, GWAS results ranked according to the lowest
association P value per gene locus but adjusted by genomic extension through case-control permutations. Compared to the previous graph, the bias
largely disappears. C, Following the rank in B, the Y-axis indicates odds ratios (ORs) of allele effects and density distributions of gene sets (driver
kinases correspond to a light lilac curve; the rest of the genome in the GWAS dataset is shown by a dark lilac curve), while the X-axis indicates the log-
transformed association P values, previously adjusted by genomic extension. As indicated by the density curves, SNPs mapping to driver kinase loci
are relatively more frequent at lower association adjusted P values. This observation is supported by GSEA results using the same CGEMS GWAS
adjusted rank; nominal P,0.001 and FDR-adjusted P=0.010 (Table S2). D, Similarly to the graph in C, distribution of CRGs in the CGEMS GWAS rank
adjusted through permutations.
doi:10.1371/journal.pone.0014078.g001
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cannot be assigned to a specific known gene–and by its focus on
the additive model of influence of risk alleles when adjusted
through case-control permutations. Future analyses taking into
account the potential perturbation of germline gene expression by,
for example, common variation at distant regulatory regions may
improve the identification of susceptibility genes using GWAS
complete data. Another limitation in the interpretation of the
results presented here may lie in the case-control study designs: the
CGEMS addressed breast cancer risk in postmenopausal women,
while the Polish study was relatively enriched in early-onset cases.
Therefore, studies in additional populations, with diverse designs,
are warranted to corroborate the results shown here.
The results of the replication study may be consistent with
previously detected somatic genetic alterations and/or functional
roles. Somatic mutations in CDKL2 were nonsense and were only
detected in breast and ovarian cancer cell lines or tumors [11,35].
CDKL2 (also known as p56 or KKIAMRE) is the most distant
member of the CDC2-related serine/threonine protein kinase
family, involved in epidermal growth factor signaling [44], but
with a mostly uncharacterized function. DYRK2 was found to be
mutated in breast and central nervous system tumors, in nonsense
and missense alterations, respectively [11,35]. The functional role
of DYRK2 in the DNA damage response [45] may link to
CGEMS GWAS results for RAD51L1 [3]: loss of DYRK2 function
alters the activation of apoptosis in response to DNA damage via
ATM [45], which may therefore promote carcinogenesis.
Having revealed potential associations linked to known somatic
alterations, the most striking results of this study may concern the
identification of risk alleles at three EPH receptor loci. EPH-
mediated signaling regulates important biological process altered
in carcinogenesis, such as cell-to-cell communication, and cell
migration and adhesion via the actin cytoskeleton [39,40]. Thus,
through RHO and RAS/MAPK activities [46], this signaling
pathway has been implicated in the maintenance of epithelial
tissue architectures and is therefore thought to act as a tumor
suppressor [39,40]. These observations may indicate that, similarly
to colorectal tumorigenesis [42], EPH-mediated compartmental-
ization of early breast tissue neoplastic lesions is critical to prevent
the subsequent emergence of carcinoma. Therefore, through a
germline expression or functional perturbation, EPHB1 may
contribute to the observed variability in the transition from an in
situ lesion to an invasive carcinoma [47]. While the associations
revealed here warrant further replication in other populations, the
existing data could potentially increase current knowledge of the
genetic basis and molecular mechanisms of breast carcinogenesis.
Materials and Methods
CGEMS dataset
The National Cancer Institute CGEMS initiative has conducted
genome-wide association studies to identify common genetic
variants and the corresponding functionally affected genes
involved in breast cancer and prostate cancer susceptibility. An
initial CGEMS whole genome scan was designed to study the
main effect of SNPs on breast cancer risk in postmenopausal
women [2]. The study involved 1,145 invasive postmenopausal
breast cancer cases and 1,142 matched controls from the Nurses’
Health Study nested case-control study [48]. Results of the
CGEMS GWAS of breast cancer were obtained upon approval of
a Data Access Request.
Table 1. Association between genetic variation in EPHB1 and
risk of breast cancer in Poland.
EPHB1, rs3732568
Controls Cases
n % n % OR 95% CI
C/C 693 79.8 891 83.2 1.00
C/A 165 19.0 172 16.1 0.79 0.62–1.00
A/A 10 1.2 8 0.7 0.60 0.23–1.55
Total 868 1,071
Trend 0.79 0.63–0.98
Ptrend=0.031
{
{Adjusted by age.
doi:10.1371/journal.pone.0014078.t001
Figure 2. Early change of EPHB1 expression in breast carcinogenesis. The graphs show expression profiles in histologically normal (HN)
breast tissues versus patient-matched atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) [41]. Results of two EPHB1 microarray
probes (names shown at the top) and the corresponding significance P values are shown.
doi:10.1371/journal.pone.0014078.g002
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Inourpreviousanalyses[26,27],ordered CGEMSGWASresults
(i.e., ranks) corresponded to the lowest P value per gene for the
genotypic test in a genomic region of +/210 kb at each gene locus,
defined by the Ensembl human genome release 57. Assigned SNPs
were curated using Ensembl gene annotations. We [26] and others
[28] noted that such ranks were biased along with the genomic
extension–and therefore with the number of SNPs–per gene locus.
To adjust for this bias, several statistical strategies are possible [28],
including carrying out permutations of the case-control status to
correct the significance of the original statistic. In our analysis,
considering typed and informative SNPs in each gene locus, we first
chose the maximum absolute value of the t statistic from the age-
adjusted partial correlation in the additive model. Next, 10,000
permutations of the same informative SNPs were performed to
create a null distribution for this maximum t statistic, which was
used to assess its significance corrected by number of SNPs.
GSEA application
The distribution of gene sets in ranked GWAS results was
examined using the non-parametric algorithm in the GSEA tool,
with default values for all parameters [31] except for the set size
when appropriated. In GSEA, a pre-defined gene set is mapped to
a rank–in our case genes/loci ordered according to the adjusted
association statistic–to assess potential bias using an enrichment
score that reflects the degree to which this set is overrepresented at
the extremes of the entire ranked list. In the interpretation of the
results, caution should be taken when considering sets of different
size. In our study, different hypotheses were examined indepen-
dently (i.e., gene sets linked to prognosis, prediction or genetic/
genomic somatic alterations), and P values were corrected for
multiple testing within each group : 1) genes whose expression in
primary breast tumors was associated with patient prognosis and/
or metastasis [49–55]; 2) genes whose expression in primary breast
tumors was associated with patient therapeutic treatment response
[56–59]; 3) genes whose expression levels differed according to
ERa breast tumor status or grade [60], or in response to 17b-
estradiol [61]; and 4) genes with somatic genetic and/or genomic
somatic alterations (Table S2). This last group was made up of five
sets : i/ driver kinases (conditional probability of containing driver
mutations .0.70, n=119 as defined previously [35], of which 95
were uniquely mapped in the GWAS rank); ii/ CRGs to
oncogenic mutations [36]; iii/ cancer gene census, somatically-
mutated only [62,63]; iv/ genes affected by somatic chromosomal
rearrangements and/or fusions [64]; and v/ amplified and over-
expressed cancer genes [65] (Table S2).
Gene expression analysis
Raw expression microarray data on breast cancer progression
[41] were downloaded from the Gene Expression Omnibus
reference GSE16873 and normalized with robust multiarray
average (RMA) [66] and significance analysis was performed using
the significance analysis of microarray (SAM) algorithm [67].
Study samples in Poland and association study
Acase-controlstudyofunselectedinvasivebreastcancercollected
between 1996 and 2003 in Szczecin (Poland) was analyzed. The
series included 976 cases of breast cancer unselected for age and an
additional group of 367 cases of breast cancer diagnosed at age 50
or below. Therefore, the series was enriched for early-onset cases:
mean age of diagnosis was 52.4 years (range 19–88). Subjects were
unselected for family history and 15% of cases reported a first- or
second-degree relative with breast cancer. The participation rate
exceeded 70% among women with breast cancer invited to enroll.
Collected information included year of birth, age at diagnosis of
breast and/or ovarian cancer, tumor bilaterality, family history
(first- and second-degree relatives with breast and/or ovarian
cancer) and tumorpathological featuresin.80% ofcases (ERa and
progesterone receptor status, and grade). Cases were also examined
for BRCA1 founder mutations in Poland [68] and, if positive,
Table 2. Associations between genetic variation in driver kinase loci and risk of breast cancer at #40 years of first age at diagnosis.
CDKL2, rs6852678
Controls Cases
n % n % OR 95% CI
C/C 39 51.3 62 51.2 1.00
C/T 28 36.8 54 44.6 1.21 0.66–2.23
T/T 9 11.8 5 4.1 0.35 0.11–1.12
Total 76 121
Recessive 0.32 0.10–1.00
Precessive=0.044
DYRK2, rs10878640
Controls Cases
n % n % OR 95% CI
G/G 42 56.8 44 35.5 1.00
G/T 24 32.4 66 53.2 2.62 1.40–4.93
T/T 8 10.8 14 11.3 1.67 0.64–4.39
Total 74 124
Dominant 2.39 1.32–4.30
Pdominant=0.003
doi:10.1371/journal.pone.0014078.t002
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included cancer-free adult women from the same population (920
womenwithmean ageofdiagnosis of56.7, range 20–91) taken from
the healthy adult patients of five family doctors practicing in the
Szczecin region. These individuals were selected randomly from the
patient lists of the participating doctors. The study was carried out
with informed consent of the probands and approved by local ethics
committees. Genotypes were obtained using Sequenom iPLEX
chemistry at the International Hereditary Cancer Center. Quality
controls were of .95% calling for each SNP and .90% of calls per
sample. Thus, in the set of 16 SNPs, we observed an average
concordance rate of 98.7% of genotype calls using 3.3% replicates.
Genotypes of 880 controls and 1,173 cases were effectively analyzed
using conditional and unconditional logistic regressions (age
adjustment using similar strata size; 20–46, 46–56, 56–66, and
66–91 years old).
Table 3. Associations of genetic variation in driver kinase loci and risk of breast cancer by ERa tumor status
{.
BMPR1A, rs12765929
Controls ERa-negative ERa-positive
n % n % OR 95% CI n % OR 95% CI
G/G 514 59.1 189 64.5 1.00 389 58.4 1.00
G/T 306 35.2 96 32.8 0.87 0.65–1.16 243 36.5 1.07 0.86–1.33
T/T 50 5.7 8 2.7 0.45 0.21–0.98 34 5.1 0.93 0.59–1.48
Total 870 293 666
Trend 0.79 0.62–1.00 1.02 0.86–1.21
Ptrend=0.050 Ptrend=0.81
Pinteraction=0.024
EPHB1, rs3732568
Controls ERa-negative ERa-positive
n % n % OR 95% CI n % OR 95% CI
C/C 693 79.8 242 82.6 1.00 563 84.9 1.00
C/A 165 19.0 49 16.7 0.81 0.57–1.16 94 14.2 0.68 0.51–0.90
A/A 10 1.2 2 0.7 0.55 0.12–2.56 6 0.9 0.72 0.26–2.00
Total 868 293 663
Trend 0.80 0.58–1.11 0.71 0.55–0.91
Ptrend=0.18 Ptrend=0.007
Pinteraction=0.56
EPHA3, rs9836340
Controls ERa-negative ERa-positive
n % n % OR 95% CI n % OR 95% CI
A/A 446 51.3 154 52.4 1.00 356 53.7 1.00
A/G 341 39.2 99 33.7 0.84 0.63–1.13 251 37.9 0.91 0.74–1.14
G/G 82 9.5 41 13.9 1.43 0.93–2.19 56 8.4 0.85 0.58–1.22
Total 869 294 663
Recessive 1.53 1.02–2.31 0.88 0.61–1.26
Precessive=0.040 Precessive=0.48
Pinteraction=0.010
EPHA7, rs4707795
Controls ERa-negative ERa-positive
n % n % OR 95% CI n % OR 95% CI
G/G 618 71.0 204 69.6 1.00 479 71.9 1.00
G/A 239 27.5 87 29.7 1.18 0.88–1.60 166 24.9 0.92 0.73–1.17
A/A 13 1.5 2 0.7 0.45 0.10–2.06 21 3.2 2.11 1.04–4.28
Total 870 293 666
Recessive 0.43 0.10–1.96 2.15 1.06–4.37
Precessive=0.28 Precessive=0.034
Pinteraction=0.007
{Adjusted by age.
doi:10.1371/journal.pone.0014078.t003
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